DAP3 and lung adenocarcinoma: Inhibition of DTYMK could restrain HCC growth and increasethe sensitivity to oxaliplatin [35].Sato et al. suggested that DAP3 is involved in the modulation of cellular radiationresponse by RIG-I-like receptor agonists in human lung adenocarcinoma cells[36].